Europe Acute Pancreatitis Market
The pancreas produces insulin, a hormone that regulates blood sugar levels. Pancreatitis can harm insulin-producing cells of pancreas, which causes diabetes in patients suffering from acute pancreatitis. People suffering from acute pancreatitis are at a twofold greater risk of diabetes as compared to the general population. Diabetes sequelae are observed across the spectrum of severity in acute pancreatitis and can accompany other clinical complications.
As per the European Review for Medical and Pharmacological Sciences, published in 2022, the prevalence of pancreatogenic diabetes is 5–10% in the Western diabetic population, and chronic pancreatitis is responsible for 20% of cases while acute pancreatitis causes 80% of cases. According to an article published in the National Library of Medicine in 2021, ~23% of acute pancreatitis patients are likely to develop diabetes within three years of discharge. Further, an article published in the Journal of Gastroenterology in 2020 states that following acute pancreatitis, ~3%, 7%, 9%, and 11% of patients develop diabetes at 6, 12, 18, and 24 months of discharge, respectively. According to an article published in the MDPI, in 2023, ~40% of patients with acute pancreatitis are affected by prediabetes and diabetes and are at a higher risk of death and readmission to hospitals than patients with type 2 diabetes. Further, ~ 60.2% of adult patients developed diabetes after acute pancreatitis, and 9% of children after acute recurrent pancreatitis or with chronic pancreatitis, and this risk increases as they age into adulthood. Researchers have noted higher diabetes incidence (~39%) after severe acute pancreatitis than mild acute pancreatitis (14%) in a meta-analysis comparing severe and mild acute pancreatitis. Thus, the increasing incidence of diabetes in patients suffering or recovering from acute pancreatitis contributes to the growth of the Europe acute pancreatitis market.
The Europe acute pancreatitis market is segmented into Germany, the UK, France, Italy, Spain, Nordic Countries, The Netherlands, and the Rest of Europe. Countries such as Germany and the UK are expected to be the largest contributors to the market in this region. The rising prevalence of acute pancreatitis and increase in alcohol consumption are the major factors driving the market growth in Europe. According to the Federal Statistical Office, health expenditure in Germany amounted to US$ 460.03 billion in 2019. It is an attractive market for companies offering therapeutic products for acute pancreatitis due to its innovative approach toward healthcare. Medical device manufacturers in Germany can also seek government funding for a variety of research projects and receive grants from the Kreditanstalt für Wiederaufbau (KfW). The increasing focus of manufacturers on new product development and strategic collaborations to develop advanced diagnostic devices such as acute pancreatitis is expected to further propel the market growth in the coming years.
The Europe acute pancreatitis market is segmented offerings, causes, end user
Based on offerings, the Europe acute pancreatitis market is segmented into medications, diagnosis, and others. The diagnosis segment held the largest market share in 2022.
Based on method, the Europe acute pancreatitis market is segmented into gallstones, alcoholism, genetic disorders, infection, and others. The gallstones segment held the largest market share in 2022.
Based on end user, the Europe acute pancreatitis market is divided into hospitals, diagnostic laboratories, ambulatory surgical centres, and others. The hospitals segment held the largest market share in 2022.
Based on country, the Europe acute pancreatitis market is segmented into the U.K., Germany, France, Italy, Spain, the Nordic Countries, the Netherlands, and the Rest of Europe. Germany dominated the Europe acute pancreatitis market share in 2022.
Abbott Laboratories, Actim Oy, Baxter International Inc, Boston Scientific Corp, Dynavax Technologies Corp, Fresenius Kabi AG, GE HealthCare Technologies Inc, Koninklijke Philips NV, Medtronic Plc, and Samsung Healthcare are some of the leading companies operating in the Europe acute pancreatitis market.
Strategic insights for the Europe Acute Pancreatitis provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 1,492.10 Million |
| Market Size by 2030 | US$ 2,260.69 Million |
| Global CAGR (2022 - 2030) | 5.3% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2030 |
| Segments Covered |
By Offerings
|
| Regions and Countries Covered | Europe
|
| Market leaders and key company profiles |
The geographic scope of the Europe Acute Pancreatitis refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.
The Europe Acute Pancreatitis Market is valued at US$ 1,492.10 Million in 2022, it is projected to reach US$ 2,260.69 Million by 2030.
As per our report Europe Acute Pancreatitis Market, the market size is valued at US$ 1,492.10 Million in 2022, projecting it to reach US$ 2,260.69 Million by 2030. This translates to a CAGR of approximately 5.3% during the forecast period.
The Europe Acute Pancreatitis Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Acute Pancreatitis Market report:
The Europe Acute Pancreatitis Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Acute Pancreatitis Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Acute Pancreatitis Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Europe Acute Pancreatitis Market
